ArticleEvidence-based complementary and alternative medicine : eCAM2004
Traditional and Modern Biomedical Prospecting: Part I-the History: Sustainable Exploitation of Biodiversity (Sponges and Invertebrates) in the Adriatic Sea in Rovinj (Croatia).
Article in Evidence-based complementary and alternative medicine : eCAM, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The need for smart microalgal bioprospecting.Natural products and bioprospecting · 2025Review
- Immunomodulatory Compounds from the Sea: From the Origins to a Modern Marine Pharmacopoeia.Marine drugs · 2024Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Review
- Marine Spongin: Naturally Prefabricated 3D Scaffold-Based Biomaterial.Marine drugs · 2018Review
- Mollusks of Candomblé: symbolic and ritualistic importance.Journal of ethnobiology and ethnomedicine · 2012Article
- Sustainable traditional medicine: taking the inspirations from ancient veterinary science.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Mumijo traditional medicine: fossil deposits from antarctica (chemical composition and beneficial bioactivity).Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Animal-based remedies as complementary medicines in the semi-arid region of northeastern Brazil.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Prognostic ability of practitioners of traditional arabic medicine: comparison with Western methods through a relative patient progress scale.Evidence-based complementary and alternative medicine : eCAM · 2010Article
- Hydroxyapatite bone substitutes developed via replication of natural marine sponges.Journal of materials science. Materials in medicine · 2010Article
- Maggot therapy: the science and implication for CAM part II-maggots combat infection.Evidence-based complementary and alternative medicine : eCAM · 2006Article
- Stem cells and CAM.Evidence-based complementary and alternative medicine : eCAM · 2006Article
- Streblus asper Lour. (Shakhotaka): A Review of its Chemical, Pharmacological and Ethnomedicinal Properties.Evidence-based complementary and alternative medicine : eCAM · 2006Article
- Tradition and perspectives of arab herbal medicine: a review.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- Bioprospecting: a CAM Frontier.Evidence-based complementary and alternative medicine : eCAM · 2005Article
- Drug Discovery, CAM and Natural Products.Evidence-based complementary and alternative medicine : eCAM · 2004Article
- Traditional and Modern Biomedical Prospecting: Part II-the Benefits: Approaches for a Sustainable Exploitation of Biodiversity (Secondary Metabolites and Biomaterials from Sponges).Evidence-based complementary and alternative medicine : eCAM · 2004Article
- Commentary on Traditional and Modern Biomedical Prospecting: Part II-The Benefits by Werner E.G. Muller, Heinz C. Schroder, Matthias Wiens, Sanja Perovic-Ottstadt, Renato Batel and Isabel M. Muller: Anti-protozoa and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin by P. Roch, A. Beschin and E. Bernard.Evidence-based complementary and alternative medicine : eCAM · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nature, especially the marine environment, provides the most effective drugs used in human therapy. Among the metazoans, the marine sponges (phylum Porifera), which are sessile filter feeders, produce the most potent and highly selective bioactive secondary metabolites. These animals (or their associated symbiotic microorganisms) synthesize secondary metabolites whose activity and selectivity has developed during their long evolutionary history (evochemistry). The exploitation of these resources has become possible due to the progress in molecular and cell biology. BIOTECmarin, the German Center of Excellence follows this rationale. In the past, these animals have been successfully and extensively utilized to isolate bioactive compounds and biomaterials for human benefit. Pharmaceuticals prepared from marine animals, primarily sponges, have been applied since ancient times (Hippocrates, Aristotle and later Plinius). It has been reported that extracts and/or components from sponges can be used for the treatment of specific diseases. For a systematic and applied-oriented exploitation, the successful development of effective compounds largely depends on quality of the institutional infrastructure of marine stations and more so on the biodiversity. The Center for Marine Research in Rovinj (Croatia) fulfils these prerequisites. Founded in 1891, this institute has to its credit major discoveries related to exploitation of secondary metabolites/biomaterials from sponges for therapeutical application and to obtain biomaterials for general wellbeing. This is the first part of a review focusing on biomedical prospecting. Here, we have mainly described the historic background. The details of techniques, substances, approaches and outlooks will be discussed in the second part.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.